The Phase 1b/2a clinical trial (NCT04445831), which was sponsored by AC Immune SA (clinical-stage biopharmaceutical company), examined the safety, tolerability, and immunogenicity of two tau-targeted liposomal vaccines, namely ACI-35.030 and JACI-35.054, in the early stages of AD. The gene discussed is MAPT; the disease is Alzheimer disease.